We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC & Springbok Collaborate on MRI Muscle Analysis for Sports
Read MoreHide Full Article
Key Takeaways
GE HealthCare partners with Springbok to combine MRI tech with AI muscle analytics.
Collaboration aims to deliver precise, quantitative insights on muscle health and recovery.
Integration could expand GE HealthCare's reach in sports medicine and performance analytics.
GE HealthCare Technologies Inc. (GEHC - Free Report) has announced a development partnership with Springbok Analytics to combine its MRI technology with Springbok’s AI-powered analysis platform, with the goal of transforming how muscle health is measured and visualized.
Traditionally, injury recovery and athletic performance are tracked using physical and functional tests that provide partial insight into internal structural changes. MRI, in contrast, offers a clearer picture of muscle condition and response to training or treatment.
By integrating AI-powered muscle analysis with advanced MRI, the collaboration seeks to deliver more precise, quantitative and actionable assessments of musculoskeletal health, supporting future advancements in sports medicine, athletic performance and wellness.
Per management, the partnership brings together Springbok’s advanced AI-based muscle analytics with GE HealthCare’s expertise in MRI acquisition and tissue characterization. The collaboration aims to unlock deeper insights from MRI data, including muscle quality, symmetry and recovery, while developing tools integrated within GEHC’s MRI platforms. The initiative is intended to advance imaging capabilities in sports medicine, human performance and longevity, aligning with the company’s broader goal of shaping the future of healthcare.
Likely Trend of GEHC Stock Following the News
Following the announcement, shares of GEHC lost 2.9% at yesterday’s closing. Over the past six months, shares of the company have dropped 6.2% compared with the industry’s 18.8% decline. However, the S&P 500 has risen 1.6% during the same timeframe.
In the long run, this collaboration strengthens GEHC’s position in advanced imaging by expanding its capabilities into AI-driven musculoskeletal analytics. The integration of quantitative muscle assessment tools with MRI platforms enhances GEHC’s value proposition in sports medicine, rehabilitation and preventive healthcare. It also opens new growth avenues in human performance and longevity-focused applications, supporting increased adoption of its imaging technologies and software solutions.
GEHC currently has a market capitalization of $32.97 billion.
Image Source: Zacks Investment Research
More on the News
At the core of this partnership is Springbok’s AI-powered platform, which transforms rapid full-body or regional MRI scans into detailed, interactive 3D maps of the musculoskeletal system. This advanced technology can quantify up to 140 individual muscles, depending on the scan type and provides objective metrics such as muscle size, asymmetry, fat infiltration, bone structure and adipose composition.
These data-driven insights are already being used by more than 80 professional sports teams and performance programs worldwide to assess musculoskeletal health, guide rehabilitation and enhance athletic performance with greater precision. Springbok’s platform has effectively set a new benchmark for quantitative muscle assessment in elite sports.
By integrating this AI-driven capability with advanced MRI imaging, the collaboration aims to unlock even deeper clinical and performance insights. The combined solution has the potential to identify muscle imbalances that may increase injury risk, monitor structural recovery to inform return-to-play decisions, and track age-related changes in muscle composition over time.
Silvia Blemker, PhD, CSO and co-founder of Springbok and professor at the University of Virginia, said that the ability to directly evaluate individual muscle structure and health has major implications for clinical care and human performance. She added that the collaboration with GE HealthCare aims to advance musculoskeletal imaging, expanding both scientific understanding and clinical impact for athletes, patients and individuals focused on maintaining strength and mobility over time.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the magnetic resonance imaging market is valued at $8.8 billion in 2026 and is expected to witness a CAGR of 3.9% through 2035.
Factors like the increasing prevalence of chronic diseases, advancements in imaging quality and high-strength applications, the growing adoption by medical professionals, the rising R&D investments and the new product launches are boosting the market’s growth.
Other News
GE HealthCare announced that View, a next-generation diagnostic imaging viewer within its Genesis Radiology Workspace, has received 510(k) clearance from the FDA. Positioned as a zero-footprint viewer and cloud-native solution, the platform allows radiologists to access diagnostic images directly through a web browser without the need for specialized on-site hardware or software installations.
GE HealthCare unveiled the latest generation of its LOGIQ general imaging ultrasound portfolio, aimed at advancing image clarity, improving workflow efficiency and strengthening diagnostic confidence. The new range — LOGIQ E10 Series, LOGIQ Fortis and LOGIQ Totus — incorporates Verisound Digital architecture along with AI-enabled capabilities to deliver enhanced imaging performance across diverse clinical applications.
GE HealthCare secured FDA 510(k) clearance for three new MRI innovations: SIGNA Sprint with Freelium, a 1.5T sealed magnet system; SIGNA Bolt, a high-performance 3T scanner; and SIGNA One, an AI-powered workflow platform that optimizes MRI processes from exam setup through post-processing.
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
GEHC & Springbok Collaborate on MRI Muscle Analysis for Sports
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) has announced a development partnership with Springbok Analytics to combine its MRI technology with Springbok’s AI-powered analysis platform, with the goal of transforming how muscle health is measured and visualized.
Traditionally, injury recovery and athletic performance are tracked using physical and functional tests that provide partial insight into internal structural changes. MRI, in contrast, offers a clearer picture of muscle condition and response to training or treatment.
By integrating AI-powered muscle analysis with advanced MRI, the collaboration seeks to deliver more precise, quantitative and actionable assessments of musculoskeletal health, supporting future advancements in sports medicine, athletic performance and wellness.
Per management, the partnership brings together Springbok’s advanced AI-based muscle analytics with GE HealthCare’s expertise in MRI acquisition and tissue characterization. The collaboration aims to unlock deeper insights from MRI data, including muscle quality, symmetry and recovery, while developing tools integrated within GEHC’s MRI platforms. The initiative is intended to advance imaging capabilities in sports medicine, human performance and longevity, aligning with the company’s broader goal of shaping the future of healthcare.
Likely Trend of GEHC Stock Following the News
Following the announcement, shares of GEHC lost 2.9% at yesterday’s closing. Over the past six months, shares of the company have dropped 6.2% compared with the industry’s 18.8% decline. However, the S&P 500 has risen 1.6% during the same timeframe.
In the long run, this collaboration strengthens GEHC’s position in advanced imaging by expanding its capabilities into AI-driven musculoskeletal analytics. The integration of quantitative muscle assessment tools with MRI platforms enhances GEHC’s value proposition in sports medicine, rehabilitation and preventive healthcare. It also opens new growth avenues in human performance and longevity-focused applications, supporting increased adoption of its imaging technologies and software solutions.
GEHC currently has a market capitalization of $32.97 billion.
Image Source: Zacks Investment Research
More on the News
At the core of this partnership is Springbok’s AI-powered platform, which transforms rapid full-body or regional MRI scans into detailed, interactive 3D maps of the musculoskeletal system. This advanced technology can quantify up to 140 individual muscles, depending on the scan type and provides objective metrics such as muscle size, asymmetry, fat infiltration, bone structure and adipose composition.
These data-driven insights are already being used by more than 80 professional sports teams and performance programs worldwide to assess musculoskeletal health, guide rehabilitation and enhance athletic performance with greater precision. Springbok’s platform has effectively set a new benchmark for quantitative muscle assessment in elite sports.
By integrating this AI-driven capability with advanced MRI imaging, the collaboration aims to unlock even deeper clinical and performance insights. The combined solution has the potential to identify muscle imbalances that may increase injury risk, monitor structural recovery to inform return-to-play decisions, and track age-related changes in muscle composition over time.
Silvia Blemker, PhD, CSO and co-founder of Springbok and professor at the University of Virginia, said that the ability to directly evaluate individual muscle structure and health has major implications for clinical care and human performance. She added that the collaboration with GE HealthCare aims to advance musculoskeletal imaging, expanding both scientific understanding and clinical impact for athletes, patients and individuals focused on maintaining strength and mobility over time.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the magnetic resonance imaging market is valued at $8.8 billion in 2026 and is expected to witness a CAGR of 3.9% through 2035.
Factors like the increasing prevalence of chronic diseases, advancements in imaging quality and high-strength applications, the growing adoption by medical professionals, the rising R&D investments and the new product launches are boosting the market’s growth.
Other News
GE HealthCare announced that View, a next-generation diagnostic imaging viewer within its Genesis Radiology Workspace, has received 510(k) clearance from the FDA. Positioned as a zero-footprint viewer and cloud-native solution, the platform allows radiologists to access diagnostic images directly through a web browser without the need for specialized on-site hardware or software installations.
GE HealthCare unveiled the latest generation of its LOGIQ general imaging ultrasound portfolio, aimed at advancing image clarity, improving workflow efficiency and strengthening diagnostic confidence. The new range — LOGIQ E10 Series, LOGIQ Fortis and LOGIQ Totus — incorporates Verisound Digital architecture along with AI-enabled capabilities to deliver enhanced imaging performance across diverse clinical applications.
GE HealthCare secured FDA 510(k) clearance for three new MRI innovations: SIGNA Sprint with Freelium, a 1.5T sealed magnet system; SIGNA Bolt, a high-performance 3T scanner; and SIGNA One, an AI-powered workflow platform that optimizes MRI processes from exam setup through post-processing.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.